Statements (121)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
gptkb:immunotherapy |
| gptkbp:affects |
immune system
|
| gptkbp:associated_with |
gptkb:adenosine_deaminase_deficiency
|
| gptkbp:can_detect |
flow cytometry
|
| gptkbp:can_lead_to |
gptkb:disease
sepsis chronic infections |
| gptkbp:cause |
gptkb:Acquired_Immunodeficiency_Syndrome
|
| gptkbp:caused_by |
genetic mutations
|
| gptkbp:characterized_by |
failure to thrive
absence of B cells absence of T cells |
| gptkbp:clinical_trial |
Ongoing for new treatments
|
| gptkbp:community_health |
Access to healthcare services
Education and awareness campaigns Global epidemic Testing and treatment as prevention |
| gptkbp:community_impact |
Discrimination against infected individuals
|
| gptkbp:condition |
gptkb:Kaposi's_sarcoma
gptkb:Pneumocystis_pneumonia Opportunistic infections |
| gptkbp:cultural_impact |
Influence on art and media
|
| gptkbp:customs |
Associated stigma
|
| gptkbp:diagnosis |
clinical evaluation
newborn screening HIV test |
| gptkbp:discovery |
gptkb:1983
|
| gptkbp:first_described_by |
1960s
|
| gptkbp:first_identified_by |
gptkb:Luc_Montagnier
gptkb:Françoise_Barré-Sinoussi |
| gptkbp:frequency |
Regular testing recommended
|
| gptkbp:funding |
Significant global funding
|
| https://www.w3.org/2000/01/rdf-schema#label |
immunotherapy
|
| gptkbp:impact_on_life_expectancy |
Near normal with treatment
Reduced without treatment |
| gptkbp:inherits_from |
gptkb:parents
X-linked or autosomal recessive |
| gptkbp:is_associated_with |
lymphopenia
failure of thymus development failure to produce antibodies |
| gptkbp:is_characterized_by |
lack of immune response
severe recurrent infections |
| gptkbp:is_common_in |
males
|
| gptkbp:is_considered |
a medical emergency
a rare disease a genetic condition a life-threatening condition a pediatric condition |
| gptkbp:is_evaluated_by |
genetic testing
immunological assessments |
| gptkbp:is_involved_in |
gptkb:CDC
gptkb:UNAIDS gptkb:WHO |
| gptkbp:is_linked_to |
gptkb:JAK3_gene_mutations
gptkb:ADA-SCID gptkb:T-B-NK+_SCID gptkb:X-SCID increased risk of cancer ADA gene mutations T-B-NK-SCID IL2 RG gene mutations RAG1 gene mutations RAG2 gene mutations |
| gptkbp:is_managed_by |
multidisciplinary teams
nutritional support supportive care isolation precautions |
| gptkbp:is_part_of |
genetic disorders
primary immunodeficiencies |
| gptkbp:is_studied_for |
gene editing techniques
immunotherapy approaches |
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:is_vulnerable_to |
No effective vaccine available
|
| gptkbp:known_as |
Bubble boy disease
|
| gptkbp:long-term_management |
Lifelong treatment required
|
| gptkbp:prevalence |
1 in 100,000 births
38 million people infected |
| gptkbp:prevention |
early diagnosis
Needle exchange programs Condom use Pre-exposure prophylaxis |
| gptkbp:public_awareness |
gptkb:World_AIDS_Day
HIV/ AIDS education |
| gptkbp:research_focus |
Vaccine development
immunological therapies Cure research |
| gptkbp:risk_factor |
Multiple sexual partners
Blood transfusions Unprotected sex Mother with HIV Sharing needles |
| gptkbp:screenings |
PCR testing
|
| gptkbp:seed_dispersal |
RNA virus
|
| gptkbp:symptoms |
gptkb:Fever
Diarrhea Fatigue Swollen lymph nodes Weight loss Skin rash increased susceptibility to infections |
| gptkbp:transmission |
gptkb:blood
Sexual contact Mother to child |
| gptkbp:treatment |
gptkb:gene_therapy
Improved quality of life stem cell therapy antibiotics antiviral medications Antiretroviral therapy bone marrow transplant immunoglobulin therapy pediatric immunologists Prevent transmission Viral suppression |
| gptkbp:treatment_adherence |
Critical for effectiveness
|
| gptkbp:type_of |
gptkb:HIV-1
gptkb:HIV-2 |
| gptkbp:bfsParent |
gptkb:biotechnology
gptkb:National_Institutes_of_Health |
| gptkbp:bfsLayer |
3
|